The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Ide-cel CAR T-cell therapy for R/R myeloma in KarMMa-3
Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the prospective Phase III KarMMa-3 study (NCT03651128) of idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T-cell therapy, for patients with relapsed/refractory (R/R) multiple myeloma. Patients with 2-4 prior lines of therapy will be randomized 2:1 to ide-cel or a standard regimen chosen based on the patient’s most recent line of therapy. The study will evaluate the safety and efficacy of ide-cel, with the hope to move CAR T-cells to an earlier line of treatment. Progression-free survival will be the primary endpoint. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ, Actinuum
